CD276 and prostate carcinoma: Recent studies have reported interactions between genetic mutations and immune checkpoints in prostate cancer, indicating that the loss of PTEN and p53 induces the expression of B7-H3, an immune checkpoint molecule, and that elevated B7-H3 contributes to tumor growth and immune suppression of T cells and NK cells in PTEN/p53-deficient tumors (128).